Suárez BLC, Noa TY, Rodríguez RI, Hernández GG, de la Uz RBO

Language: Spanish
References: 19
Page: 25-33
PDF size: 197.56 Kb.

ABSTRACT

An observational, descriptive and cross-sectional study was conducted in 17 adults with acute promyelocitic leukemia, attended in the "Dr. Juan Bruno Zayas Alfonso" General Teaching Hospital of Santiago de Cuba during a five-year period to evaluate the effectiveness of induction therapy with arsenic trioxide. In the case series the complete hematologic remission was obtained in 82.4% of patients at 42.2 days on average. Hepatotoxicity and bone pain prevailed as the most common adverse reactions, as well as severe bleeding as main cause of death. With this treatment the return to work of those who improved completely was achieved and overall survival to date is 76.4%.

REFERENCES

1. Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988; 72: 567-72.

2. Ramos Peñafiel CO, Castellanos Sinco H, Montaño E, Martínez Murillo C, Lavielle P, García Vidrios V. Experiencia del tratamiento de la leucemia promielocítica aguda (LAP) en el Hospital General de México: protocolo LAP 2001. Rev Hematol Mex. 2009; 10 (supl2): 57.

3. Taliman MS, Andersen JW, Schiffer CA. Clinical description of 44 patiens with acute promyelocyticleucemia who Developer the retinoic acid syndrome. Blood. 2000; 95(1):90-5.

4. Zhu J, Okumura H, Ohtake S, Nakamura S, Nakao S. The molecular mechanism of arsenic-induced apoptosis and oncosis in lucemia/lymphoma cell lines. Acta Haematol. 2003; 110 (1):1-10.

5. Ablain J, The H. Revisiting the differentiation paradigm in acute promyelocitic leukemia. Blood. 2011; 117(22): 5795-5802.

6. Sweeney J, Takimoto C, Wood L, Porter JM, Tracevel WG, Darwish M, et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010; 66:345-56

7. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukaemia and direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009; 27(22):3650.

8. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29(20): 2753-7.

9. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, followup, and molecular monitoring in 11newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94(10):3315-24.

10. Lazo G, Kantarjian H, Estey E, Thomas D, O´Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia. Cancer. 2003; 97:2218-24.

11. Miller W, Schipper H, Lee J, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002; 62:3893–903.

12. Sanz M, Fenaux P, Lo Coco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematol. 2005; 90:1231-5.

13. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107(7):2627-32.

14. Jin Zhou, Yingmei Zhang, Jinmei Li, Xiaoxia Li, Jinxiao Hou, Yanqiu Zhao. Singleagent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010; 115(9): 1697-1702.

15. Hu J, Liu YF, Wu CF, Xu F, Shere ZX, Zhue YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Nat Acad Sci. 2009; 106(6):3342-7.

16. Mathews V, Jijina F, Ross C. Single agent arsenic trioxide regimen for the treatment of newly diagnosed acute promyelocytic leukemia: a multicenter randomized controlled study from India to study the optimal duration of arsenic trioxide maintenance therapy (IAPLSG04). Blood. 2009; 114: 822.

17. De la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acidand idarubicin. Blood. 2008; 111(7): 3395-3402.

18. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumabozogamicin. J Clin Oncol. 2009; 27(4):504-10.

19. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009; 114:5126-35.